Latin America moves on rimonabant and drug safety
This article was originally published in Scrip
Executive Summary
Regulatory authorities in Latin America have responded quickly to theEMEA's recommendation last week to suspendSanofi-Aventis's obesity treatment Acomplia (rimonabant) owing to concerns over increased risk of psychiatric disorders (ScripOnline, October 24th, 2008).